<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html id="nojs" xmlns="http://www.w3.org/1999/xhtml" xmlns:m="http://www.w3.org/1998/Math/MathML" xmlns:og="http://ogp.me/ns#" xml:lang="en-GB" lang="en-GB" xmlns:wb=“http://open.weibo.com/wb”>

<head>

   
  
      
  
                  
  
                  
  
            
  
            
            
    <title>Trials | Full text | Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial</title>
<link rel="shortcut icon" type="image/x-icon" href="/images/icon/10096/favicon.ico" />
<link rel="apple-touch-icon" sizes="72x72" href="/sites/10096/images/70.gif" />
<meta http-equiv="X-UA-Compatible" content="IE=7" />


                
    
		
		
		
		
<!-- <?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:cc="http://web.resource.org/cc/" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
<cc:Work rdf:about="http://www.trialsjournal.com/content/16/1/42">
<cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
</cc:Work>
<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
<cc:permits rdf:resource="http://web.resource.org/cc/Reproduction"/>
<cc:permits rdf:resource="http://web.resource.org/cc/Distribution"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Notice"/>
<cc:requires rdf:resource="http://web.resource.org/cc/Attribution"/>
<cc:permits rdf:resource="http://web.resource.org/cc/DerivativeWorks"/>
</cc:License>
<item rdf:about="http://www.trialsjournal.com/content/16/1/42">
<title>Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial</title>
<dc:title>Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial</dc:title>
<dc:creator>Aitken, Emma</dc:creator>
<dc:creator>Geddes, Colin</dc:creator>
<dc:creator>Thomson, Pete</dc:creator>
<dc:creator>Kasthuri, Ram</dc:creator>
<dc:creator>Chandramohan, Mohan</dc:creator>
<dc:creator>Berry, Colin</dc:creator>
<dc:creator>Kingsmore, David</dc:creator>
<dc:identifier>info:doi/10.1186/s13063-015-0556-x</dc:identifier>
<dc:source>Trials 2015, 16:42</dc:source>
<dc:date>2015-02-08</dc:date>

<prism:publicationName>Trials</prism:publicationName>
<prism:publicationDate>2015-02-08</prism:publicationDate>
<prism:volume>16</prism:volume>
<prism:number>1</prism:number>
<prism:section>Study protocol</prism:section>
<prism:startingPage>42</prism:startingPage>
<prism:copyright>2015 Aitken et al.; licensee BioMed Central.</prism:copyright>
</item>
</rdf:RDF>
 -->
 
 
<meta name="citation_journal_title" content="Trials" />
<meta name="citation_publisher" content="BioMed Central Ltd" />


<meta name="citation_author" content="Emma Aitken" />
<meta name="citation_author_institution" content="Department of Renal Surgery, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK" />
<meta name="citation_author_institution" content="School of Medical, Veterinary and Life Science, University of Glasgow, University Avenue, Glasgow G12 8TA, UK" />
<meta name="citation_author" content="Colin Geddes" />
<meta name="citation_author_institution" content="Department of Nephrology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK" />
<meta name="citation_author" content="Pete Thomson" />
<meta name="citation_author_institution" content="Department of Nephrology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK" />
<meta name="citation_author" content="Ram Kasthuri" />
<meta name="citation_author_institution" content="Department of Radiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK" />
<meta name="citation_author" content="Mohan Chandramohan" />
<meta name="citation_author_institution" content="Department of Radiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK" />
<meta name="citation_author" content="Colin Berry" />
<meta name="citation_author_institution" content="British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Avenue, Glasgow G12 8TA, UK" />
<meta name="citation_author" content="David Kingsmore" />
<meta name="citation_author_institution" content="Department of Renal Surgery, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK" />


<meta name="citation_issn" content="1745-6215" />
<meta name="citation_title" content="Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial" />
<meta name="citation_volume" content="16" />
<meta name="citation_issue" content="1" />
<meta name="citation_date" content="2015-02-08" />
<meta name="citation_firstpage" content="42" />
<meta name="citation_doi" content="10.1186/s13063-015-0556-x" />
<meta name="citation_pdf_url" content="http://www.trialsjournal.com/content/pdf/s13063-015-0556-x.pdf" />
<link rel="alternate" type="application/pdf" title="PDF" href="http://www.trialsjournal.com/content/pdf/s13063-015-0556-x.pdf" />
<meta name="title" content="Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial" />
<meta name="description" content="Autologous arteriovenous fistulae (AVF) are the optimal form of vascular access for haemodialysis. AVFs typically require 6 to 8&nbsp;weeks to &ldquo;mature&rdquo; from the time of surgery before they can be cannulated. Patients with end-stage renal disease needing urgent vascular access therefore traditionally require insertion of a tunnelled central venous catheter (TCVC). TCVCs are associated with high infection rates and central venous stenosis." />

<meta name="dc.title" content="Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial" />
<meta name="dc.creator" content="Aitken, Emma" />
<meta name="dc.creator" content="Geddes, Colin" />
<meta name="dc.creator" content="Thomson, Pete" />
<meta name="dc.creator" content="Kasthuri, Ram" />
<meta name="dc.creator" content="Chandramohan, Mohan" />
<meta name="dc.creator" content="Berry, Colin" />
<meta name="dc.creator" content="Kingsmore, David" />
<meta name="dc.description" content="Autologous arteriovenous fistulae (AVF) are the optimal form of vascular access for haemodialysis. AVFs typically require 6 to 8&nbsp;weeks to &ldquo;mature&rdquo; from the time of surgery before they can be cannulated. Patients with end-stage renal disease needing urgent vascular access therefore traditionally require insertion of a tunnelled central venous catheter (TCVC). TCVCs are associated with high infection rates and central venous stenosis." />
<meta name="dc.source" content="Trials 2015 16:42" />
<meta name="dc.format" content="text/html" />
<meta name="dc.publisher" content="BioMed Central Ltd" />
<meta name="dc.date" content="2015-02-08" />
<meta name="dc.type" content="Study protocol" />
<meta name="dc.identifier" content="10.1186/s13063-015-0556-x" />
<meta name="dc.language" content="en" />
<meta name="dc.copyright" content="2015 Aitken et al.; licensee BioMed Central." />
<meta name="dc.rights" content="http://creativecommons.org/licenses/by/2.0/" />
<meta name="dc.rightsAgent" content="reprints@biomedcentral.com" />

<meta name="prism.issn" content="1745-6215" />
<meta name="prism.publicationName" content="Trials" />
<meta name="prism.publicationDate" content="2015-02-08" />
<meta name="prism.volume" content="16" />
<meta name="prism.number" content="1" />
<meta name="prism.section" content="Study protocol" />
<meta name="prism.startingPage" content="42" />
<meta name="prism.copyright" content="2015 Aitken et al.; licensee BioMed Central." />
<meta name="prism.rightsAgent" content="reprints@biomedcentral.com" />


        <meta name="citation_abstract_html_url" content="http://www.trialsjournal.com/content/16/1/42/abstract" />
            <meta name="citation_fulltext_html_url" content="http://www.trialsjournal.com/content/16/1/42" />
            <link rel='alternate' type='text/xml' title='XML version' href='http://www.trialsjournal.com/content/download/xml/s13063-015-0556-x.xml' />
            <link rel="image_src" href="http://www.trialsjournal.com/content/figures/s13063-015-0556-x-toc.gif" />
    
    
    
    
                    
    

<script type="text/javascript">
// must run before css
document.documentElement.id = "js";
</script>



						
   
  
      
  
                  
  
                  
  
            
  
            
            



						
        <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery-1.8.2.min-0.js"></script>

	                <link rel="stylesheet" type="text/css" href="/css/main-0.css" media="screen, print"/>
    
                <link rel="stylesheet" type="text/css" href="/css/plugins-0.css" media="screen, print"/>
    



    

			                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/articles-0.css" media="screen, print"/>
    	

    

    <link rel="stylesheet" type="text/css" href="/css/themes/10096.css" media="screen, print"/>


                <link rel="stylesheet" type="text/css" href="/css/media/print-0.css" media="print"/>
    



<!--[if IE]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie-0.css"/>
    <![endif]-->

<!--[if IE 7]>
                    <link rel="stylesheet" type="text/css" href="/css/hacks/ie7-0.css"/>
    <![endif]-->
			
<script type="text/javascript">
    //configuration
    OAS_url = '//oas.biomedcentral.com/RealMedia/ads/';

	// control of advert's position on page [AMC]
    
    	
	
    OAS_sitepage = "trialsjournal.com/article/10.1186/s13063/015/0556/x";
    	
		OAS_listpos = 'Top,x96,Right3';
	
	
			
		OAS_query = '';
		
	

    OAS_target = '_top';
    //end of configuration
    OAS_version = 10;
    OAS_rn = '001234567890'; OAS_rns = '1234567890';
    OAS_rn = new String (Math.random()); OAS_rns = OAS_rn.substring (2, 11);
    function OAS_NORMAL(pos) {
		document.write('<a href="' + OAS_url + 'click_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" target="' + OAS_target + '">');
		document.write('<img src="' + OAS_url + 'adstream_nx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '!' + pos + '?' + OAS_query + '" border="0"/></a>');
    }
    
	function refererTerms(referer) {

	if(referer.match("q=") != null) {
		referer = referer.split("q=");
		referer = referer[1].split("&");
		referer = referer[0];
	} else {
		referer = referer;
	}

		if(referer.match("%20") != null && referer.match("%20").length >= 1) {
			referer =  referer.replace(/%20/gi,"+");
			return referer;
		} else { 
			return referer; 
		}
	}
 </script>


 <script type="text/javascript">
	// Set the version of JavaScript to 10 for a Browser 'Mozilla/3' on webTV 
    OAS_version = 11;
    if ((navigator.userAgent.indexOf('Mozilla/3') != -1) || (navigator.userAgent.indexOf('Mozilla/4.0 WebTV') != -1)) {
     OAS_version = 10; }
    if (OAS_version >= 11) {
    document.write('<scr' + 'ipt type="text/javascript" src="' + OAS_url + 'adstream_mjx.ads/' + OAS_sitepage + '/1' + OAS_rns + '@' + OAS_listpos + '?' + OAS_query + '"><\/script>'); }
</script>
	
<script type="text/javascript">
    document.write('');
	
    function OAS_AD(pos) {
        if (OAS_version >= 11)
         OAS_RICH(pos);
        else
         OAS_NORMAL(pos);
    }
 </script>
	





<script type="text/javascript">
    jsonLoaders = function(){
        var _loaders = [];
        return {
            register: function(config){
                config.prefix = config.prefix || '/webapi/1.0/blogs/';
                config.feedLength = config.feedLength || 3;

                _loaders.push(config);
            },
            list: function(){return _loaders}
        };
    }();

    function totext() {
	    document.write('<a href="javascript:returnToText();">Return to text</a>');
    }

    function retrieve_doi(){
        var metas = document.getElementsByTagName('meta');
        var i;
        for (i = 0; i < metas.length; i++)
            if (metas[i].getAttribute('name') == "citation_doi")
                break;
        var citation_doi = metas[i].getAttribute('content');
        return citation_doi;
    }

</script>





    <script src="http://tjs.sjs.sinajs.cn/open/api/js/wb.js" type="text/javascript" charset="utf-8"></script>
        <link title="Latest articles" rel="alternate" href="http://www.trialsjournal.com/latest/rss" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Most viewed" rel="alternate" href="http://www.trialsjournal.com/mostviewed/rss/" type="application/rss+xml" exposeToHeader="true"/>
    <link title="Latest comments" rel="alternate" href="http://www.trialsjournal.com/latestcomments/rss" type="application/rss+xml" exposeToHeader="true"/>
    


	<script type="text/javascript">
	var _gaq = _gaq || [];
	_gaq.push(['_setAccount', 'UA-9663741-5']);
	_gaq.push(['_gat._anonymizeIp']);
	_gaq.push(['_setLocalRemoteServerMode']);
	
	/*for cross domain tracking*/
	//_gaq.push(['_setAllowLinker', true]);
    //_gaq.push(['_setDomainName', 'trialsjournal.com']); //this journal's domain
	/**/
	
		_gaq.push(['_trackPageview']); 

	(function() {
		var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true;
		ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js';
		var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s);

		//var iframe = document.getElementById('casesdb-search-widget');
		//if(iframe !== null) {
		//	var pageTracker = _gat._getTrackerByName();
		//	iframe.src = pageTracker._getLinkerUrl('http://www.casesdatabase.com/');
		//}
	})();
	</script>

	
        </head>


<body class=" theme    ">


        



   
  
      
  
                  
  
                  
  
            
  
            
            

    

<div id="oas-campaign" style="display:none">trialsjournal.com/article/10.1186/s13063/015/0556/x</div>
<div id="oas-positions" style="display:none">Bottom,Top</div>

<div id="branding" role="banner">
                			
		<dl class="google-ad wide ">
	<dt class="hide">
					<a class="banner-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising"></a>
				
			</dt>
		<dd>

		<!-- OAS AD 'Top' begin -->
		<script type="text/javascript">
		OAS_AD('Top');

		</script>
		<!-- OAS AD 'Top' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad wide noscript">  
    <dt class="hide"></dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0556/x/13480475383@Top?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0556/x/17482111505@Top?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
			            <div class="sup-panel-outer">
        <div class="sup-panel-inner">

            <style>
  #nojs li.greeting, #nojs li#loginLink {display:none;}
</style>


<ul id="login" class="login">

    <noscript><li><a href="/log"><img class="greeting" src="/images/log.gif"/></a></li></noscript>
    
    <li id="welcome"><span id="username"></span></li>

    <li id="loginLink"><a href=""></a></li>
    
    
</ul>

<script>

function login() {

/* cookie getter/setter */
var allCookies = {
  getItem: function (sKey) {
    if (!sKey || !this.hasItem(sKey)) { return null; }
    return unescape(document.cookie.replace(new RegExp("(?:^|.*;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=\\s*((?:[^;](?!;))*[^;]?).*"), "$1"));
  },
  setItem: function (sKey, sValue, vEnd, sPath, sDomain, bSecure) {
    if (!sKey || /^(?:expires|max\-age|path|domain|secure)$/i.test(sKey)) { return; }
    var sExpires = "";
    if (vEnd) {
      switch (vEnd.constructor) {
        case Number:
          sExpires = vEnd === Infinity ? "; expires=Tue, 19 Jan 2038 03:14:07 GMT" : "; max-age=" + vEnd;
          break;
        case String:
          sExpires = "; expires=" + vEnd;
          break;
        case Date:
          sExpires = "; expires=" + vEnd.toGMTString();
          break;
      }
    }
    document.cookie = escape(sKey) + "=" + escape(sValue) + sExpires + (sDomain ? "; domain=" + sDomain : "") + (sPath ? "; path=" + sPath : "") + (bSecure ? "; secure" : "");
  },
  removeItem: function (sKey, sPath) {
    if (!sKey || !this.hasItem(sKey)) { return; }
    document.cookie = escape(sKey) + "=; expires=Thu, 01 Jan 1970 00:00:00 GMT" + (sPath ? "; path=" + sPath : "");
  },
  hasItem: function (sKey) {
    return (new RegExp("(?:^|;\\s*)" + escape(sKey).replace(/[\-\.\+\*]/g, "\\$&") + "\\s*\\=")).test(document.cookie);
  },
  keys: /* optional method: you can safely remove it! */ function () {
    var aKeys = document.cookie.replace(/((?:^|\s*;)[^\=]+)(?=;|$)|^\s*|\s*(?:\=[^;]*)?(?:\1|$)/g, "").split(/\s*(?:\=[^;]*)?;\s*/);
    for (var nIdx = 0; nIdx < aKeys.length; nIdx++) { aKeys[nIdx] = unescape(aKeys[nIdx]); }
    return aKeys;
  }
};

// converts cookie into js object
function parseCookie(cookie) {

    cookie = cookie.split("&");
    var obj = {};

    for(var i = 0; i < cookie.length; i++) {

        var c = cookie[i].split("=");

        c[0] = c[0].replace('"','');
        
        obj[c[0]] = c[1];

    }
    return obj;
}

    var cookie = allCookies.getItem("bmccookie");

    var obj = (cookie != null) ? parseCookie(cookie) : {};
    

        var welcome = "";

        if(obj.hasOwnProperty("fname")) {

            // insert user welcome
            welcome = obj.fname.replace(/\+/g, " ") + " " + obj['lname'].replace(/\+/g," ");

            if(jQuery("#welcome").length > 0) {
              jQuery("#welcome").prepend("<strong>Welcome</strong> ");
              jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log off");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logoff");

            window.bmcloggedon = true;


        } else if(obj.hasOwnProperty("institution_name")) {

            // insert institution name
            welcome = obj["institution_name"].replace(/\+/g," ");
            
            if(jQuery("#welcome").length > 0) { 
                jQuery("#welcome").prepend("<strong>Welcome</strong> ");
                jQuery("#username").prepend('<strong>' + welcome + '</strong><span class="divider"></span>');
            } 

            // update link url
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;


        } else {
            jQuery("#welcome").innerHTML = "";
            jQuery("#loginLink a").text("Log on");
            jQuery("#loginLink a").attr("href", window.location.protocol + "//" + window.location.host + "/logon");

            window.bmcloggedon = false;

        }


        // if athens login cookie doesn't exist and the athens login link is visible then remove it.
        if(allCookies.hasItem("athens") != true && document.getElementById("loginAthensLink") != null) {
          jQuery("#loginAthensLink").hide();
        }

}

login();


</script>

            <ul class="nav-sup">

    
        <li id="BMC" class="current">
            <a href="http://www.biomedcentral.com/"><span class="img-title">&nbsp;</span>
            <span class="text-title">BioMed Central</span></a>
        </li>
		
        		<li><a href="http://www.biomedcentral.com/journals"><span>Journals</span></a></li>
		
								<li>
				<a href="http://www.biomedcentral.com/gateways"><span>Gateways</span></a>
			</li>
					    	
</ul>
        </div>
    </div>
    <div class="branding-inner">

        

    
<style>
.survey {
	margin: 10px 0;
}
.survey, .survey .survey-sentence {
	font-size: 13px;
}
.survey-button a, .survey-button a:active, .survey-button a:visited, .survey-button a:hover  {
    color: #FFFFFF;
    text-decoration: none;
}
.survey-button {
	background-color: #FFA500;
    border-radius: 5px;
    color: #FFFFFF;
    font-weight: bold;
    font-size: 13px;
    font-weight: bold;
    padding: 5px 13px;
    background: #ef8142; /* Old browsers */
	background: -moz-linear-gradient(top,  #ef8142 0%, #ef8142 50%, #a64510 100%, #a64510 100%); /* FF3.6+ */
	background: -webkit-gradient(linear, left top, left bottom, color-stop(0%,#ef8142), color-stop(50%,#ef8142), color-stop(100%,#a64510), color-stop(100%,#a64510)); /* Chrome,Safari4+ */
	background: -webkit-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Chrome10+,Safari5.1+ */
	background: -o-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* Opera 11.10+ */
	background: -ms-linear-gradient(top,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* IE10+ */
	background: linear-gradient(to bottom,  #ef8142 0%,#ef8142 50%,#a64510 100%,#a64510 100%); /* W3C */
	filter: progid:DXImageTransform.Microsoft.gradient( startColorstr='#ef8142', endColorstr='#a64510',GradientType=0 ); /* IE6-9 */

}
</style>




          <div class="logo">
        <a href="/"><img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" /></a>     
      </div>    
        
                    



            <div id="impact-factor" class="official">
    <img src="/images/branding/official.gif" alt="official impact factor" title="2.12"/>
    <span id="impact-factor-value">2.12</span>
</div>
    
                            

<div class="module search gray small  " role="search">
    <div class="module-inner padded">
        <form method="get" class="searchForm"
              action=" /quickSearchRedirectURL "
              onsubmit="window.location.href=this['url'].value + '?terms=' + encodeURIComponent(this['terms'].value); return false;">
            <fieldset class="search">
			                <span>
                    Search <select name="url">
                                <option value="http://www.trialsjournal.com/search/results" selected>Trials</option>
                                <option value="http://www.biomedcentral.com/search/results">BioMed Central</option>
                           </select> for
                </span>
                            <input id="searchTerms" name="terms" type="text" alt="Search terms" class="text " />
                 <button class="w37" value="Go" type="submit">Go</button>
            </fieldset>
        </form>
    </div>
	<a class="advanced-search" href="/search">Advanced search</a>
</div> 

                        <div id="mobile-nav-list" >

	<ul class="primary-nav" role="navigation">
		<li     ><a href="/"><span id="home-tab">Home</span></a></li>
														<li             class="current"
    ><a href="/content"><span id="articles-tab">Articles</span></a></li>
										
	

	
            <li     ><a href="/authors/instructions"><span id="authors-tab">Authors</span></a></li>
        <li     ><a href="/about/reviewers"><span id="reviewers-tab">Reviewers</span></a></li>
    		<li     ><a href="/about"><span id='about-tab'>About this journal</span></a></li>
	<li     ><a href="/my"><span id="my-tab">My Trials</span></a></li>
		
    		</ul>
</div>
            </div>
</div>

<hr class="hide" />
<div class="container">
	<div id="content"  class="overflow-visible"  role="main">
			    
	

<!--div class="branding-mobile">
		<h1 class="logo">
	    <a href="/">
		    <img alt="Trials" title="Trials Logo" src="/sites/10096/images/logo.gif" />
		</a>
		</h1>
	</div><br/-->



			
	



<div class="outline-wrapper block mobile-hidden" id="left-article-box">
<ul id="box-outline" class="box">
<ul id="outline" class="outline">
   <li>
      <a href="#">Top</a>
   </li>
   <li>
      <a href="#abs">Abstract</a>
   </li>
   <li>
      <a href="#sec1">Background</a>
   </li>
   <li>
      <a href="#sec2">Methods/design</a>
   </li>
   <li>
      <a href="#sec3">Discussion</a>
   </li>
   <li>
      <a href="#sec4">Trial status</a>
   </li>
   <li>
      <a href="#sec5">Abbreviations</a>
   </li>
   <li>
      <a href="#sec6">Competing interests</a>
   </li>
   <li>
      <a href="#sec7">Authors’ contributions</a>
   </li>
   <li>
      <a href="#ack">Acknowledgements</a>
   </li>
   <li class="lowest">
      <a href="#refs">References</a>
   </li>
</ul>
</ul>

<dl id="box-outline1">
</dl>

				



</div>



<div class="mobile-hidden" id="right-panel">
 	
<div id="mobile-sidebar">
	<div id="mobile-sidebar-tab">
		<span>
			<a href="#" id="mobile-sidebar-tab-link"><img src="/images/sidebar-hidden.png"><img style="display:none;" src="/images/sidebar-shown.png"></a>
		</span>
	</div>	<div id="mobile-sidebar-list">

<div id="article-navigation-bar">
    <div class="issue-information block">
        <h5><a href="http://www.trialsjournal.com"><strong>Trials</strong></a></h5>
 		        <ul class="square normal">
            <li><a href="http://www.trialsjournal.com/content/16">Volume 16</a></li>
				
                    </ul>
    </div>

    <div class="article-information block" id="article-info">
        


<div id="viewing-options-links">
	<h5>Viewing options</h5>
	<ul class="square normal">
        
            <li>
                             <a onclick="_gaq.push(['_trackEvent', 'Abstract', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/16/1/42/abstract">Abstract</a>
                        </li>
        				<li>
							<strong>Full text</strong>
					</li>
				
		<li class="pdfFileSize">
			<a onclick="_gaq.push(['_trackEvent', 'PDF download', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/pdf/s13063-015-0556-x.pdf">PDF</a>
			<span>(422KB)</span>
		</li>

        
			</ul>

        
</div>
		
<div id="associated-material-links">
    <h5>Associated material</h5>
    <ul class="square normal">
                                    <li><a onclick="_gaq.push(['_trackEvent', 'Article metrics', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/16/1/42/about">Article metrics</a></li>
                <li>
                        <a onclick="_gaq.push(['_trackEvent', 'Readers comments', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/16/1/42/comments">Readers' comments </a>
                    </li>
        <li>
                            <a onclick="_gaq.push(['_trackEvent', 'Pre-publication history', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/16/1/42/prepub">Pre-publication history</a>                    </li>
    </ul>
</div>
		




<div id="related-literature-links">
    <h5>Related literature</h5>
    <ul class="normal">
                    <li><a onclick="_gaq.push(['_trackEvent', 'Citied by', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://www.trialsjournal.com/content/16/1/42/about#citations">Cited by</a></li>
                <li id="google-blog-search"><a onclick="_gaq.push(['_trackEvent', 'Google blog search', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://www.google.com/search?tbm=blg&hl=en&amp;source=hp&amp;biw=1280&amp;bih=899&amp;q=%22Immediate+access+arteriovenous+grafts+versus+tunnelled+central+venous+catheters%3A+study+protocol+for+a+randomised+controlled+trial%22&amp;btnG=Search">Google blog search</a></li>
        <h6>Other articles by authors</h6>
        <li>
            <a class="collapser"><i>&nbsp;</i>on Google Scholar</a>
<ul id="authg" class="hidebeforeload">                         <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22E+Aitken%22">Aitken E</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22C+Geddes%22">Geddes C</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22P+Thomson%22">Thomson P</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22R+Kasthuri%22">Kasthuri R</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22M+Chandramohan%22">Chandramohan M</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22C+Berry%22">Berry C</a>
            </li>
                                <li>
                <a href="http://scholar.google.com/scholar?q=author%3A%22D+Kingsmore%22">Kingsmore D</a>
            </li>
            </ul>          </li>
                <li>
            	        </li>
    </ul>     <h6>Related articles/pages</h6>
    <ul class="square normal">
        <li><a onclick="_gaq.push(['_trackEvent', 'on google', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://www.google.co.uk/search?hl=en&amp;q=related:http://www.trialsjournal.com/content/16/1/42">on Google</a></li>
        <li><a onclick="_gaq.push(['_trackEvent', 'on google scholar', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://scholar.google.com/scholar?q=related:http://www.trialsjournal.com/content/16/1/42">on Google Scholar</a></li>
            </ul>

</div>		
        
    
    
        

    	






<h5>Tools</h5>
	<ul class="square normal">
									<li>
						<a onclick="_gaq.push(['_trackEvent', 'download references', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/16/1/42/citation">Download references</a>
					</li>
				<li><a onclick="_gaq.push(['_trackEvent', 'download xml', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/download/xml/s13063-015-0556-x.xml">Download XML</a></li>
				<li>
						<a onclick="_gaq.push(['_trackEvent', 'email2friend', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/16/1/42/email">Email to a friend</a>
					</li>
		<li><a onclick="_gaq.push(['_trackEvent', 'order reprints', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="https://www.odysseypress.com/onlinehost/reprint_order.php?type=A&page=0&journal=738&doi=10.1186/s13063-015-0556-x&volume=16&issue=1&title=Immediate+access+arteriovenous+grafts+versus+tunnelled+central+venous+catheters%3A+study+protocol+for+a+randomised+controlled+trial&author_name=Emma Aitken&start_page=1&end_page=7">Order reprints</a></li>
		<li>
						<a onclick="_gaq.push(['_trackEvent', 'post a comment', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/16/1/42/postcomment">Post a comment</a>
					</li>			
		<ul id="download-to-links">
			<a class="downloadto_title btn" href="#"><span class="icon">&nbsp;</span>Download to ...</a>
			
			<ul id="downloadto" class="iconlist hidebeforeload" style="display: none;">
				<li>
					<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F42" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/42', 1, true]);"><span class="share-icons papers"></span>Papers</a>
				</li>
				<li>
					<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/42" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/42', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
				</li>
			</ul>
		</ul>
		
		<ul id="mobile-downloadto" class="iconlist">
		
		<h6>Download to ...</h6>
			<li>
				<a href="http://redirect.papersapp.com/redirect?url=http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F42" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Papers', 'Article Sidebar', '/content/16/1/42', 1, true]);"><span class="share-icons papers"></span>Papers</a>
			</li>
			
			<li>
				<a href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/42" target="_blank" onclick="_gaq.push(['_trackEvent', 'Download to Mandeley', 'Article Sidebar', '/content/16/1/42', 1, true]);"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
		</ul>

		
	</ul>
		




<h5>Share this article</h5>
<ul id="social-networking-links">
	<li>
	<div class="fb-like" onclick="_gaq.push(['_trackEvent', 'Facebook Recommend', 'Article Sidebar', '/content/16/1/42', 1, true]);" data-href="http://www.trialsjournal.com/content/16/1/42" data-send="false" data-layout="button_count" data-width="100" data-show-faces="false" data-action="recommend"></div>
	</li>
	<li>
		<a onclick="_gaq.push(['_trackEvent', 'Share Twitter Recommend', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://twitter.com/share" data-url="http://www.trialsjournal.com/content/16/1/42" data-counturl="http://www.trialsjournal.com/content/16/1/42" data-hashtags="trials
" data-text="Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial" class="twitter-share-button">Tweet</a>
	</li>
	<li>
			<g:plusone size="medium" width="100"></g:plusone>
	</li>

        <li>
        <wb:share-button onclick="_gaq.push(['_trackEvent', 'Recommend Google plus', 'Article Sidebar', '/content/16/1/42', 1, true]);" addition="number" type="button" ralateUid="2216240737" title="Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial http://www.trialsjournal.com/content/16/1/42"></wb:share-button>
    </li>
    
		<a class="sharethis_title btn" href="#"><span class="icon">&nbsp;</span>More options...</a>
	<ul class="iconlist hidebeforeload" id="sharethis">
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'citeu Like', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://www.citeulike.org/posturl?url=http://www.trialsjournal.com/content/16/1/42"><span class="share-icons citeulike"></span>Citeulike</a>
			</li>
				<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Linkedin', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://www.linkedin.com/shareArticle?mini=true&url=%26%2335%3Btrials%0D%0AImmediate%20access%20arteriovenous%20grafts%20versus%20tunnelled%20central%20venous%20catheters%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F42&title=Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial"><span class="share-icons linkedin"></span>LinkedIn</a>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share delicious', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://del.icio.us/post?url=http://www.trialsjournal.com/content/16/1/42&title=Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial"><span class="share-icons delicious"></span>Del.icio.us</a>
	</li>
			<li>
				<a onclick="_gaq.push(['_trackEvent', 'Share via email', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="/content/16/1/42/email"><span class="share-icons email"></span>Email</a>
	</li>
			<li>
				<a onclick="target="_blank" onclick="_gaq.push(['_trackEvent', 'Share facebook', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://www.facebook.com/sharer.php?u=http://www.trialsjournal.com/content/16/1/42"><span class="share-icons facebook"></span>Facebook</a>
	</li>
	<li class="gp">
			<div class="googlehider mobile-hide"> 
				<div class="g-plusone" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus mobile-hide"></span>
				<div class="googlehider2 mobile-hide"> 
				<div class="g-plusone mobile-hide" data-annotation="none"></div>
			</div>
				<span class="share-icons googleplus"></span>
				<span class="gp-link"><a  onclick="_gaq.push(['_trackEvent', 'Share google plus', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="#">Google+</a></span>
	</li>
			<li>
				<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share Mandeley', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://www.mendeley.com/import/?url=http://www.trialsjournal.com/content/16/1/42"><span class="share-icons mendeley"></span>Mendeley</a>
			</li>
			<li>
			<a target="_blank" onclick="_gaq.push(['_trackEvent', 'Share twitter icon', 'Article Sidebar', '/content/16/1/42', 1, true]);" href="http://twitter.com/?status=Immediate%20access%20arteriovenous%20grafts%20versus%20tunnelled%20central%20venous%20catheters%3A%20study%20protocol%20for%20a%20randomised%20controlled%20trial%20http%3A%2F%2Fwww.trialsjournal.com%2Fcontent%2F16%2F1%2F42+%23trials
"><span class="share-icons twitter"></span>Twitter</a>
			</li>

			<li><a href="http://www.reddit.com/submit" onclick="window.location = 'http://www.reddit.com/submit?url=http://www.trialsjournal.com/content/16/1/42'; return false"> <span class="share-icons reddit"></span>Reddit</a>
    </li>






		</ul>
</ul>

    </div>

    
  
        
                
        


















                                                                                
	

	    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="signup-to-etoc" class="button-collection-margins block mobile-border-bottom">	
					<h3>Email updates</h3>
			<p id="receive_issue_alerts_journal_updates_text">Keep up to date with the latest news and content from Trials and BioMed Central.</p>
			
				
<form  id="articleSignupForUpdates"  method="post" action="/signuptoupdates.html">
	<div id="message-box"></div>
    <fieldset class="block-form">
        <input type="text" name="emailAddress" onblur="javascript: if (this.value == '') { this.value = 'email address'; }" onfocus="javascript: if (this.value == 'email address') { this.value = ''; }" value="email address"  class="text " id="email" />
        <input value="" type="hidden" name="returnUrl" id="returnUrl" />
        <input value="xniche-trials" type="hidden" name="listName" id="listName" />
        <input value="Trials" type="hidden" name="journalName" id="journalName" />
        <button onclick="_gaq.push('_trackEvent', 'Signup', 'Signup for Email updates', "Trials");" class="w74 right" type="submit" onmouseover="this.className='w74 hover right'" onmouseout="this.className='w74 right'" value="Sign up">Sign up</button>
    </fieldset>
</form>	
</div>

	


			<div id="advert-offset">
    					
		<dl class="google-ad  ">
	<dt class="hide">
				
					<a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
			</dt>
		<dd>

		<!-- OAS AD 'Right3' begin -->
		<script type="text/javascript">
		OAS_AD('Right3');

		</script>
		<!-- OAS AD 'Right3' end -->
		</dd>

		</dl>

		<noscript>
			<dl class="google-ad  noscript">  
    <dt class="hide"><a href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</dt>
    
    <dd>
        <a href="//oas.biomedcentral.com/RealMedia/ads/click_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0556/x/19098543904@Right3?">
            <img src="//oas.biomedcentral.com/RealMedia/ads/adstream_nx.ads/trialsjournal.com/article/10.1186/s13063/015/0556/x/13447612529@Right3?" alt="advert"/>
        </a>
    </dd>
			</dl>
		</noscript>
					</div>
	

	
</div>
		<div class="mobile-sidebar-gradient top"></div>
		<div class="mobile-sidebar-gradient bottom"></div>
	</div>

</div>








 </div>
<div class="rounded custom white article full-text">
<div class="wrap-inner content">
    <div class="padded-inner">            


    
   
  
      
  
                  
  
                  
  
            
  
            
            

<div id="topmatter">
	


	   






 
  



				<a href="/about/access"><img alt="Open Access" src="/images/articles/openaccess-large.png" class="access mr15"/></a>
			<a href="http://www.biomedcentral.com/about/mostviewed/"><img alt="Highly Accessed" src="/images/articles/highlyaccessed-large.png" class="access mr15"/></a>
				<span class="articletype">Study protocol</span>

<h1>Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial</h1>
        
			<div class="multipleins">
		
	<p class="authors">
        																																																																																																																																																																																																																																				         <strong>Emma Aitken</strong><sup><a href="/content/16/1/42/#ins1">1</a></sup><sup><a href="/content/16/1/42/#ins2">2</a></sup><sup>&#42;</sup>, <strong>Colin Geddes</strong><sup><a href="/content/16/1/42/#ins3">3</a></sup>, <strong>Pete Thomson</strong><sup><a href="/content/16/1/42/#ins3">3</a></sup>, <strong>Ram Kasthuri</strong><sup><a href="/content/16/1/42/#ins4">4</a></sup>, <strong>Mohan Chandramohan</strong><sup><a href="/content/16/1/42/#ins4">4</a></sup>, <strong>Colin Berry</strong><sup><a href="/content/16/1/42/#ins5">5</a></sup> and <strong>David Kingsmore</strong><sup><a href="/content/16/1/42/#ins1">1</a></sup>	</p>
	
				<div id="affiliations">
		<div class="module gray  inner">
<div class="module-inner padded-inner">
		<ul>
			<li>                        
                                                                                                    		<p class="authors" >
							<span>*</span>
									 Corresponding author:										            Emma  Aitken <a href='mailto:e.aitken.1@research.gla.ac.uk'>e.aitken.1@research.gla.ac.uk</a>    					</p>
      
</li>
			
                                                                                                                                                                                                                    		</ul>

		
		 <p class="options"><a class="affiliations-toggle" href="#"><i class="arrow"></i>Author Affiliations</a></p>            <section> 
						<div class="collapsible-content">
							
				<div id="ins_container" style="display: block;">
										    						    <p >
						        <sup id="ins1">1</sup>                                Department of Renal Surgery, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK
                            </p>
																    						    <p >
						        <sup id="ins2">2</sup>                                School of Medical, Veterinary and Life Science, University of Glasgow, University Avenue, Glasgow G12 8TA, UK
                            </p>
																    						    <p >
						        <sup id="ins3">3</sup>                                Department of Nephrology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK
                            </p>
																    						    <p >
						        <sup id="ins4">4</sup>                                Department of Radiology, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK
                            </p>
																    						    <p >
						        <sup id="ins5">5</sup>                                British Heart Foundation Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Avenue, Glasgow G12 8TA, UK
                            </p>
																
				</div>
										<p id="authoremails">            For all author emails, please <a href="/logon">log on</a>.
    </p>
						</div>
			</section>
				</div>
</div>
		</div>
	  </div>

            <section class="cit">
                        <div class="collapsible-content">
        <p><em>Trials</em> 2015, <strong>16</strong>:42&nbsp;
			<span class="pseudotab">doi:10.1186/s13063-015-0556-x</span></p>
	    				    
    
        
                
		<p>The electronic version of this article is the complete one and can be found online at: <a href="http://www.trialsjournal.com/content/16/1/42">http://www.trialsjournal.com/content/16/1/42</a></p>
		<br/>
                    <table cellspacing="0" cellpadding="0">
        <tbody>
        <tr><td>Received:</td><td>1 June 2014</td></tr>                <tr><td>Accepted:</td><td>7 January 2015</td></tr>        <tr><td>Published:</td><td>8 February 2015</td></tr>        </tbody>
        </table>
    		<!--<br/>-->
		<div  style="line-height:140%">
        <p>
            &copy; 2015 Aitken et al.; licensee BioMed Central. <br />
        </p>
					<p>
				This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
			</p>
		    	</div>
	</section>

</div>
<div id="article-body">
    <section><a name="abs"></a><h3>Abstract</h3>
   <div class="collapsible-content">
      <h4>Background</h4>
      <p style="line-height:160%">Autologous arteriovenous fistulae (AVF) are the optimal form of vascular access for
         haemodialysis. AVFs typically require 6 to 8&nbsp;weeks to “mature” from the time of surgery
         before they can be cannulated. Patients with end-stage renal disease needing urgent
         vascular access therefore traditionally require insertion of a tunnelled central venous
         catheter (TCVC). TCVCs are associated with high infection rates and central venous
         stenosis.
      </p>
      <p style="line-height:160%">Early cannulation synthetic arteriovenous grafts (ecAVG) provide a novel alternative
         to TCVCs, permitting rapid access to the bloodstream and immediate needling for haemodialysis.
         Published rates of infection in small series are low.
      </p>
      <p style="line-height:160%">The aim of this study is to compare whether TCVC ± AVF or ecAVG ± AVF provide a better
         strategy for managing patients requiring immediate vascular access for haemodialysis.
      </p>
      <h4>Methods/design</h4>
      <p style="line-height:160%">This is a prospective randomised controlled trial comparing the strategy of TCVC ± AVF
         to ecAVG ± AVF. Patients requiring urgent vascular access will receive a study information
         sheet and written consent will be obtained. Patients will be randomised to receive
         either: (i) TCVC (and native AVF if this is anatomically possible) or (ii) ecAVG (±
         AVF).
      </p>
      <p style="line-height:160%">118 patients will be recruited. The primary outcome is systemic bacteraemia at 6&nbsp;months.
         Secondary outcomes include culture-proven bacteraemia rates at 1&nbsp;year and 2&nbsp;years;
         primary and secondary patency rates at 3, 6, 12 and 24&nbsp;months; stenoses; re-intervention
         rates; re-admission rate; mortality and quality of life. Additionally, treatment delays,
         impact on service provision and cost-effectiveness will be evaluated.
      </p>
      <h4>Discussion</h4>
      <p style="line-height:160%">This is the first randomised controlled trial comparing TCVC to ecAVG for patients
         requiring urgent vascular access for haemodialysis. The complications of TCVC are
         considered an unfortunate necessity in patients requiring urgent haemodialysis who
         do not have autologous vascular access. If this study demonstrates that ecAVGs provide
         a safe and practical alternative to TCVC, this could instigate a paradigm shift in
         nephrology thinking and access planning.
      </p>
      <h4>Trial registration</h4>
      <p style="line-height:160%">This study has been approved by the West of Scotland Research Ethics Committee 4 (reference
         no. 13/WS/0087, 28 August 2013) and is registered with the International Standard
         Randomised Controlled Trial Number Register (reference no. <a href="ISRCTN80588541">ISRCTN80588541</a> <a href="http://www.webcitation.org/query.php?url=ISRCTN80588541&amp;refdoi=10.1186/s13063-015-0556-x" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a>, 27 May 2014).
      </p>
   </div>
</section><span id="keywords">
   <h5 class="inline">Keywords: </h5>Tunnelled central venous catheter; Arteriovenous graft; Vascular access; End-stage renal disease</span><section><a name="sec1"></a><h3>Background</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Vascular access dysfunction is the leading cause of morbidity amongst patients with
         end-stage renal disease (ESRD) and is a key performance indicator for haemodialysis
         service provision <a name="d80443e198"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>]. Complications of vascular access are responsible for over 20% of all hospitalisations
         in patients on haemodialysis and account for one-third of all inpatient renal bed
         use <a name="d80443e202"></a>[<a onclick="LoadInParent('#B2'); return false;" href="#B2">2</a>].
      </p>
      <p style="line-height:160%">Autologous arteriovenous fistulae (AVFs) are the vascular access modality of choice
         <a name="d80443e208"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>],<a name="d80443e212"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>] with fewer infective and thrombotic complications than the alternatives <a name="d80443e216"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>],<a name="d80443e220"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>]: tunnelled central venous catheters (TCVCs) and prosthetic arteriovenous grafts (AVGs).
         The major limitations to native AVF usage are a 6 to 8&nbsp;week “maturation” lag from
         creation to first cannulation and 30 to 50% early failure rate <a name="d80443e224"></a>[<a onclick="LoadInParent('#B5'); return false;" href="#B5">5</a>],<a name="d80443e229"></a>[<a onclick="LoadInParent('#B6'); return false;" href="#B6">6</a>]. Unfortunately, due to a combination of late referral, primary access failure and
         acute presentation of renal failure, 40 to 50% of incident patients do not have a
         functioning AVF when they commence dialysis <a name="d80443e233"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>],<a name="d80443e237"></a>[<a onclick="LoadInParent('#B7'); return false;" href="#B7">7</a>],<a name="d80443e241"></a>[<a onclick="LoadInParent('#B8'); return false;" href="#B8">8</a>]. Given the unpredictable progression of decline in renal function to ESRD <a name="d80443e245"></a>[<a onclick="LoadInParent('#B9'); return false;" href="#B9">9</a>],<a name="d80443e249"></a>[<a onclick="LoadInParent('#B10'); return false;" href="#B10">10</a>] and the fact that 30 to 35% of patients needing to start haemodialysis are “crashlanders”
         (known to the renal services for &lt;90&nbsp;days) <a name="d80443e254"></a>[<a onclick="LoadInParent('#B3'); return false;" href="#B3">3</a>], whilst desirable, it is not always practicably possible to achieve autologous vascular
         access for all patients prior to commencing haemodialysis. Current practice necessitates
         TCVC for these patients until definitive vascular access can be secured. Patients
         who began haemodialysis via a TCVC are more likely to remain with TCVC <a name="d80443e258"></a>[<a onclick="LoadInParent('#B11'); return false;" href="#B11">11</a>]; therefore, optimizing incident vascular access is vitally important.
      </p>
      <p style="line-height:160%">TCVCs are associated with a significantly higher risk of infection, mortality, mechanical
         complications and other chronic problems such as immunosuppression, malnutrition and
         central venous stenosis than other forms of vascular access <a name="d80443e264"></a>[<a onclick="LoadInParent('#B1'); return false;" href="#B1">1</a>],<a name="d80443e268"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>]. A recent Scottish study of 2,666 patients revealed a two- to threefold increased
         risk in mortality (all-cause mortality, cardiovascular or infection-related mortality)
         and a sevenfold increase in death from septicaemia with the use of TCVCs <a name="d80443e272"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>]. For these reasons, TCVC are considered an option of last resort.
      </p>
      <p style="line-height:160%">AVGs provide an intermediate option between AVF and TCVCs, permitting earlier cannulation
         than AVF but lower bacteraemia rates than TCVC (0.6 per 1,000 dialysis days) <a name="d80443e278"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>]. The longevity and patency of AVGs are variable and almost certainly poorer than
         native AVF with 1-year primary patency rates ranging from 40 to 60% <a name="d80443e282"></a>[<a onclick="LoadInParent('#B14'); return false;" href="#B14">14</a>]. However, with aggressive re-intervention for the management of thrombosis, secondary
         patency rates of as high as 90% at 1&nbsp;year can be achieved <a name="d80443e286"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>].
      </p>
      <p style="line-height:160%">Traditional AVGs still require a delay of approximately 2&nbsp;weeks from implantation
         to initial cannulation, compelling TCVC insertion as a stop-gap measure in the majority
         of cases. However, early cannulation arteriovenous grafts (ecAVGs), which permit immediate
         needling, may provide a novel alternative permitting TCVC avoidance in many cases
         <a name="d80443e292"></a>[<a onclick="LoadInParent('#B16'); return false;" href="#B16">16</a>]. The GORE<strong>®</strong> Acuseal™ (W.L.Gore Associates Ltd., Flagstaff, Arizona) vascular access graft is
         one such ecAVG. It is a tri-layer graft with unique sealing properties to permit safe
         cannulation within 24&nbsp;hours of insertion. The tri-layer construction comprises an
         inner layer of heparinised expanded polytetrafluoroethylene, an outer layer of standard
         expanded polytetrafluoroethylene graft, and a central elastomeric layer <a name="d80443e299"></a>[<a onclick="LoadInParent('#B17'); return false;" href="#B17">17</a>]. This central layer gives the graft its unique “low bleed” properties and permits
         early cannulation, reducing the time to achieve haemostasis significantly compared
         to standard expanded polytetrafluoroethylene.
      </p>
      <p style="line-height:160%">These unique properties of Acuseal™ and other ecAVGs make them an attractive alternative
         to TCVCs in patients requiring urgent vascular access for haemodialysis with theoretical
         benefits of reduced infection and avoidance of long-term TCVC complications such as
         central venous stenosis. In small series, the Acuseal™ graft has been shown to be
         beneficial in patients requiring urgent access for haemodialysis as a “bridge” to
         AVF maturation or transplantation, as well as in patients with pre-existing occlusion
         of their central veins <a name="d80443e305"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]. A recent observational study conducted in our unit has indicated that ecAVG provide
         a practical, feasible and acceptable alternative to TCVCs in patients requiring urgent
         vascular access for haemodialysis <a name="d80443e309"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>]. Furthermore, cost-analysis has shown that the additional initial outlay costs of
         consumables can be offset against reduced septic complications, hospital admissions
         and bed days, with potential cost savings of nearly £1,000 at 6&nbsp;months with ecAVG
         compared to TCVCs <a name="d80443e313"></a>[<a onclick="LoadInParent('#B20'); return false;" href="#B20">20</a>].
      </p>
      <p style="line-height:160%">We now intend to test this hypothesis in a randomised controlled trial comparing TCVCs
         (± AVF) to ecAVG (±AVF).
      </p>
   </div>
</section>
<section><a name="sec2"></a><h3>Methods/design</h3>
   <div class="collapsible-content">
      <h4>Overview</h4>
      <p style="line-height:160%">This is a single centre randomised controlled trial. This study has been approved
         by the West of Scotland Research Ethics Committee 4 (reference no. 13/WS/0087) and
         is registered with the International Standard Randomised Controlled Trial Number Register
         (<a href="ISRCTN80588541">ISRCTN80588541</a> <a href="http://www.webcitation.org/query.php?url=ISRCTN80588541&amp;refdoi=10.1186/s13063-015-0556-x" alt="" title="Archive copy of webpage" class="xpushbutton">webcite</a>). This study will be performed in keeping with the requirements of the Declaration
         of Helsinki.
      </p>
      <h4>Hypothesis</h4>
      <p style="line-height:160%">The use of ecAVGs ± AVFs will reduce the rate of culture-proven bacteraemia at 6&nbsp;months
         compared to the use of TCVCs ± AVFs in patients with ESRD requiring urgent vascular
         access for haemodialysis.
      </p>
      <h4>Objectives and outcome measures</h4>
      <p style="line-height:160%">This study aims for a strategy of comparing ecAVG ± autologous AVF (if anatomically
         suitable) to TCVC ± autologous AVF in patients requiring urgent vascular access for
         haemodialysis. The primary outcome measure is culture-proven bacteraemia at 6&nbsp;months.
         Secondary outcomes include culture-proven bacteraemia at 12 and 24&nbsp;months; primary,
         secondary and functional patency rates at 3, 6, 12 and 24&nbsp;months; stenosis, thrombosis
         and re-intervention rates (including the need for urokinase infusions, AVG declotting
         procedures and TCVC replacement); other complications, including local infection,
         suspected access-related infection, steal syndrome, cardiovascular compromise, central
         venous stenosis; mortality at 6, 12 and 24&nbsp;months, quality of life (assessed by EQ-5D)
         at 6&nbsp;months; future sites of vascular access; re-admission rates and bed day utilisation
         and efficiency and efficacy of dialysis (urea reduction ratio, access flows, and recirculation).
         Additionally delays to treatment and the impact on service provision (access to theatre,
         and so forth) will be assessed to evaluate the practicalities of each treatment regimen.
         Cost-utility analysis will also be performed. Definitions of patency and other access-related
         complications will be as described by Sidawy and colleagues <a name="d80443e344"></a>[<a onclick="LoadInParent('#B21'); return false;" href="#B21">21</a>].
      </p>
      <h4>Study centre</h4>
      <p style="line-height:160%">The study will be conducted at the Western Infirmary, Glasgow, UK. This university
         teaching hospital provides a tertiary referral vascular access service for 650 haemodialysis
         patients in the West of Scotland. We perform approximately 400 vascular access procedures,
         including 100 complex access procedures, annually. We have a wealth of experience
         using ecAVGs with published local outcomes highlighting our current practice <a name="d80443e354"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]-<a name="d80443e358"></a>[<a onclick="LoadInParent('#B20'); return false;" href="#B20">20</a>]. The necessary volume of clinical cases, presence of clinical expertise and equipment
         required for this study is well established in this unit.
      </p>
      <h4>Patients and enrolment</h4>
      <p style="line-height:160%">All patients will be admitted under the care of the Nephrology Team at the Western
         Infirmary. Patients requiring urgent vascular access for haemodialysis will be assessed
         by their clinical team. Temporary venous catheter will be inserted to permit life-saving
         haemodialysis if required. The clinical team will then refer the patient to the Vascular
         Access Co-ordinator for TCVC insertion and definitive vascular access creation.
      </p>
      <p style="line-height:160%">All patients referred for TCVC insertion will be assessed by a member of the research
         team within 6&nbsp;hours of referral. All adult patients (≥18&nbsp;years old) with ESRD requiring
         urgent vascular access for haemodialysis will be eligible to participate. Patients
         will be excluded if they have significant cardiorespiratory co-morbidities or peripheral
         vascular disease precluding anaesthesia or ecAVG creation, a brachial artery &lt;2&nbsp;mm
         diameter on duplex ultrasound, significant and untreated systemic sepsis with positive
         blood cultures, women who are pregnant or breast-feeding, lack of capacity or ability
         to provide informed consent or if they decline to participate.
      </p>
      <h4>Consent</h4>
      <p style="line-height:160%">The process of consent will be in accordance with the Declaration of Helsinki. All
         suitable patients will be fully informed that they are being asked to participate
         in a research study. The procedures involved in the study, and the chances of being
         assigned randomly to one of two groups will be explained in person and via an information
         sheet approved by the West of Scotland Ethics Committee. A signed consent form will
         be obtained from each patient and retained by the investigators. Patients will be
         made aware of their right to withdraw from the study at any time without adverse effects
         on their clinical care.
      </p>
      <h4>Pre-operative management</h4>
      <p style="line-height:160%">All patients will undergo Duplex ultrasound of both arms. Both the venous and arterial
         tree will be assessed and a pre-operative plan made to site both ecAVG and native
         AVF. Wherever possible, care will be taken to preserve all sites for future autologous
         access and the site of native AVF will always be favoured in the non-dominant arm
         and distally first. ecAVG will be placed to accommodate optimal AVF placement. For
         example, a native left radiocephalic fistula and right forearm loop or right brachioaxillary
         graft would be favoured in a left-handed patient with good native vessels and no previous
         vascular access; whilst revision of an existing occluded left brachiocephalic fistula
         with outflow stenosis using an interposition ecAVG and contralateral elbow AVF would
         be considered in an elderly patient with poor vessels and occluded existing AVF.
      </p>
      <h4>Randomisation</h4>
      <p style="line-height:160%">A computer generated 1:1 allocation sequence will be created by an independent operator
         who is not directly involved with the study. Allocation concealment will be achieved
         using sequentially numbered sealed opaque envelopes.
      </p>
      <h4>Blinding</h4>
      <p style="line-height:160%">Due to the nature of the treatment and any subsequent interventions, it is not possible
         to blind either patient, surgeon or investigator to the treatment allocation.
      </p>
      <h4>Treatment strategies</h4>
      <p style="line-height:160%">Patients will be randomized to receive either ecAVG ± AVF or TCVC ± AVF.</p>
      <h4>TCVC ± AVF</h4>
      <p style="line-height:160%">TCVC ± AVF reflects standard practice at our institution. Patients randomized to receive
         TCVC ± AVF will be referred to the Interventional Radiology Department for TCVC insertion
         (either by a radiologist or nurse specializing in TCVC insertion).
      </p>
      <p style="line-height:160%">Tunnelled Ash Split<strong>®</strong> (Medcomp, Harleysville, PA, USA) 14Fr double-lumen polyurethane haemodialysis catheters
         will be inserted with 280- or 320-mm catheters used for right- and left-sided cannulation,
         respectively. Catheters will be inserted via a Seldinger technique under image guidance.
         A standard catheter care protocol will be employed throughout the study period. This
         demands complete sterile precautions during catheter insertion and upon manipulation
         of the hub. Following catheter hub manipulation, the skin surrounding the insertion
         site is soaked with chlorhexidine solution prior to a sterile dressing being applied.
         An interdialytic lock with heparin 5,000 iU/ml to the internal volume of the catheter
         will be employed.
      </p>
      <p style="line-height:160%">First haemodialysis via the TCVC will be performed by trained nursing staff within
         the InPatient Renal Unit at the Western Infirmary. A record of any difficulties or
         complications with initial dialysis will be made. The timing of the first dialysis
         via the TCVC will be made at the discretion of the nephrology team, as will the need
         for anticoagulation. A record of these factors will be kept.
      </p>
      <p style="line-height:160%">The patient will be discharged to dialyse at their Outpatient Dialysis Unit at the
         discretion of the nephrology team. Any problems that subsequently develop with the
         TCVC will be referred to and managed by the nephrology team at the Western Infirmary
         as is standard practice. These will be recorded in the patient’s electronic patient
         record and reported to the Principal Investigator.
      </p>
      <h4>ecAVG ± AVF</h4>
      <p style="line-height:160%">Patients randomised to the ecAVG ± AVF arm of the study will be immediately assessed
         by a member of the anaesthetic team. An operative slot will be found within either
         emergency or elective theatres at the Western Infirmary for ecAVG creation within
         24&nbsp;hours.
      </p>
      <p style="line-height:160%">All patients will be treated with pre-operative prophylactic vancomycin 1&nbsp;g intravenously
         (or teicoplanin if the patient is vancomycin allergic). ecAVG insertion will be performed
         by a single operating surgeon either under supraclavicular block or general anaesthetic.
      </p>
      <p style="line-height:160%">The patient’s skin will be prepared with alcoholic betadine, draped in a standard
         fashion and an Ioban™ skin covering (3&nbsp;M Healthcare, Bracknell, UK) applied to maintain
         strict asepsis. The vessels will be exposed and controlled in a standard fashion.
         The Acuseal™ graft will then be tunnelled in the subcutaneous fat using standard tunnelling
         tools. A 4-cm longitudinal venotomy will be performed and the graft spatulated at
         the venous end in an attempt to minimize venous stenosis. The arteriotomy will be
         a standard size to accommodate the graft. Arterial and venous anastomoses will be
         performed using continuous 5.0 Prolene. Collatamp™ (Tribute Pharmaceuticals, Milton,
         Ontario, Canada) will be inserted into the wounds prior to closure to minimize the
         risk of infection. Drains will be placed at the surgeon’s discretion.
      </p>
      <p style="line-height:160%">Post-operatively the patient will be managed within the Inpatient Renal Unit of the
         Western Infirmary. First cannulation of the ecAVG will be performed by our trained
         dialysis nursing staff in agreement between the Nephrology and Surgical Teams as the
         patient’s clinical condition dictates. This may be as soon as 30&nbsp;minutes post-operatively.
      </p>
      <p style="line-height:160%">Sharp needles (17&nbsp;G), low flows (200 to 250&nbsp;ml/min) and minimal heparin will be used
         for first cannulation of ecAVGs. Full aseptic technique will be used for cannulation
         and direct pressure applied at the needle sites for at least 10&nbsp;minutes after the
         needles have been removed. These same techniques will be used for the first 2&nbsp;weeks
         of cannulation. Thereafter, higher flow rates may be used if necessary to achieve
         adequate dialysis clearance. Success and complications of dialysis sessions and cannulation
         will be recorded. At least two successful cannulations of the ecAVG will be performed
         prior to discharge to the Outpatient Dialysis Unit. All patients will continue on
         intravenous vancomycin for a week post-operatively. Heparin, warfarin and anti-platelet
         agents will be administered at the discretion of the operating surgeon. All patients
         who re-present with thrombotic complications will be anti-coagulated with warfarin
         (international normalised ratio 2–3) unless contraindicated.
      </p>
      <p style="line-height:160%">Should the patient develop any problems with their ecAVG upon discharge they will
         be reviewed immediately by a member of the Renal Surgical Team at the Western Infirmary
         as is standard practice. In the event of thrombosis of ecAVG, aggressive attempts
         will be made by both the surgical and radiological teams to salvage the dialysis access
         as is standard practice. All complications will be recorded within the patient’s electronic
         case record and reported to the research team.
      </p>
      <h4>Autologous AVF</h4>
      <p style="line-height:160%">Patients in both treatment arms will also undergo creation of an autologous AVF (if
         this is anatomically possible) at the first available opportunity. The ecAVG/TCVC
         will continue to be utilized for haemodialysis until the AVF is mature enough to cannulate.
         The decision to undertake first cannulation of the AVF will be taken by the clinical
         team (normally ~6&nbsp;weeks after creation) and recorded within the patient’s electronic
         patient record.
      </p>
      <p style="line-height:160%">Once the patient is successfully dialyzing via their AVF, the fate of an ecAVG, which
         is no longer required, will be decided after discussion between the patient and surgical
         team. In the majority of cases it will be left <em>in situ</em> but can be removed or ligated if required/wished. TCVCs will be removed by the surgical
         team after six successful AVF cannulations as is standard practice.
      </p>
      <h4>Follow-up and data collection</h4>
      <p style="line-height:160%">All patients will be reviewed by the research team on day 1, day 7 and 3, 6, 12 and
         24&nbsp;months following insertion of ecAVG/TCVC and 6&nbsp;weeks following creation of AVF.
         Additionally surveillance of ecAVG will be performed by both ultrasound and venography
         at 3-monthly intervals. Data will be collected prospectively from the operative notes
         and Scottish Electronic Renal Patient Record.
      </p>
      <p style="line-height:160%">Patient demographics will be obtained including age, gender, ethnicity, weight, body
         mass index, dialysis status, current access modality and co-morbidities. Details of
         operative surgery, anaesthetic, site of ecAVG, TCVC and AVF and perioperative complications
         will be recorded. Date and details of first cannulation/utilisation of ecAVG/TCVC
         will be recorded in the case report form along with the date and nature of any complications.
         Quality of life will be assessed at 6, 12 and 24&nbsp;months. All data will be anonymised.
         Case report files will be archived in a locked facility for a period of 5&nbsp;years.
      </p>
      <h4>Criteria for discontinuation</h4>
      <p style="line-height:160%">Every effort will be made to retain patients in the trial and to minimise withdrawals.
         However, any severe or life-threatening event will be sufficient to remove a patient
         from the study. Data collected prior to the point of withdrawal from the study will
         be retained. Patients may request to be withdrawn from this study at any time. Reasons
         for withdrawal will be documented. Intention-to-treat analysis will be performed.
      </p>
      <h4>Sample size and statistical considerations</h4>
      <p style="line-height:160%">Locally, 24% of TCVCs result in systemic bacteraemia within 6&nbsp;months <a name="d80443e463"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>]. In order to calculate sample size, we made the following assumptions: type 1 error
         (α) was set at 0.05 and type 2 error (β) at 0.8. Therefore, if we assume a systemic
         bacteraemia rate in the TCVC arm of 24% at 6&nbsp;months and propose a bacteraemia rate
         of 5% at 6&nbsp;months in the ecAVG arm, then 53 patients are required in each group. In
         order to account for attrition of around 10%, we aim to recruit 118 patients. This
         magnitude of difference between the two treatment arms is considered to be clinically
         significant and realistic given the published rates of systemic bacteraemia for ecAVG
         in our institution <a name="d80443e467"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>].
      </p>
      <p style="line-height:160%">The null hypothesis for this study is that there is no difference between systemic
         bacteraemia rates at 6&nbsp;months in patients who require urgent vascular access for haemodialysis
         treated with TCVC ± AVF and those treated with ecAVG ± AVF.
      </p>
      <p style="line-height:160%">Descriptive statistics will be used to describe continuous variables. Results for
         continuous variables will be reported as mean (± standard deviation) or median (interquartile
         range). Assuming normal distribution, treatment groups will be compared using a student’s
         t-test or, if data are found to not be normally distributed, a Mann–Whitney U-test
         will be used. Analysis will be performed on an intention-to-treat basis. Additionally,
         a cost-consequence analysis will be conducted, comparing the costs (for example, treatment,
         procedures, hospital stay, and so forth) and the consequences (for example, health
         outcomes such as bacteraemia episodes, mortality, and so forth) of both treatment
         arms.
      </p>
      <p style="line-height:160%">Based on the results of our recent observational study <a name="d80443e477"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>] in which 53 eligible patients presented in a 6-month period, it is anticipated that
         recruitment will take approximately 18&nbsp;months. Data collection will continue for 2&nbsp;years
         beyond the date of last recruitment, though the primary outcome will be assessed after
         6&nbsp;months.
      </p>
      <h4>Adverse event reporting and safety</h4>
      <p style="line-height:160%">All adverse events will be fully recorded in the medical records and on the study
         case report forms. A Data Monitoring Committee comprising of the Chief Investigator,
         trial statistician and an independent nephrologist will convene at the mid-point of
         the trial to evaluate recruitment and data collection. The Data Monitoring Committee
         will monitor adverse events and make recommendations as required. An interim analysis
         of results will be performed at the mid-point of the trial.
      </p>
      <p style="line-height:160%">All adverse events will be evaluated by the Chief Investigator for severity, expectedness
         and causality. Any serious adverse events (SAEs) will be reported to the main Research
         Ethics Committee and sponsor where, in the opinion of the Chief Investigator, the
         event was related (resulted from administration of any of the research procedures)
         and unexpected (not listed in the protocol as an expected outcome). SAEs will be reported
         using the National Research Ethics Service SAE report form for Clinical Trials of
         Non-Investigational Medical Products.
      </p>
      <p style="line-height:160%">Both TCVCs and AVGs are used routinely in clinical practice with minimal complications.
         The most common risk of TCVC usage is systemic bacteraemia, quoted in the range of
         1.4 to 1.8 per 1,000 catheter days <a name="d80443e491"></a>[<a onclick="LoadInParent('#B4'); return false;" href="#B4">4</a>],<a name="d80443e495"></a>[<a onclick="LoadInParent('#B12'); return false;" href="#B12">12</a>],<a name="d80443e499"></a>[<a onclick="LoadInParent('#B13'); return false;" href="#B13">13</a>],<a name="d80443e503"></a>[<a onclick="LoadInParent('#B22'); return false;" href="#B22">22</a>]. Most commonly, Gram-positive organisms, for example <em>Staphylococcus Aureus</em>, cause catheter-related bacteremia <a name="d80443e511"></a>[<a onclick="LoadInParent('#B23'); return false;" href="#B23">23</a>]. Otherwise, catheter replacement for dysfunction (thrombosis and malposition) occurs
         in approximately 0.2 per 1,000 catheter days <a name="d80443e515"></a>[<a onclick="LoadInParent('#B23'); return false;" href="#B23">23</a>]. The well-described complications of pneumothorax and carotid artery puncture are
         very rare with image-guided TCVC insertion.
      </p>
      <p style="line-height:160%">Similarly, operative complications of ecAVG, including steal syndrome and bleeding,
         are rare <a name="d80443e521"></a>[<a onclick="LoadInParent('#B18'); return false;" href="#B18">18</a>]. Infection rates are lower than TCVC (approximately 0.6 per 1,000 dialysis days in
         most published series). The most common infective organisms are Gram-negatives, which
         are more common in lower rather than upper limb accesses <a name="d80443e525"></a>[<a onclick="LoadInParent('#B24'); return false;" href="#B24">24</a>]. Thrombosis of ecAVG is the most common complication, with approximately half of
         ecAVGs requiring re-intervention during the first year <a name="d80443e529"></a>[<a onclick="LoadInParent('#B14'); return false;" href="#B14">14</a>]. With aggressive management strategies for thrombosis, however, it is possible to
         achieve secondary patency rates approaching 90% at 1&nbsp;year <a name="d80443e533"></a>[<a onclick="LoadInParent('#B15'); return false;" href="#B15">15</a>].
      </p>
      <p style="line-height:160%">Any adverse events relating to either procedure will be recorded by the staff performing
         the study, and necessary investigations, treatment or follow-up arranged thereafter.
      </p>
      <h4>Limitations and potential solutions</h4>
      <p style="line-height:160%">Traditionally, recruitment in trials relating to vascular access can be difficult.
         In one recent large study, over 2,000 patients were screened to recruit just 225 <a name="d80443e545"></a>[<a onclick="LoadInParent('#B25'); return false;" href="#B25">25</a>]. This study had very strict inclusion criteria, which can be difficult to achieve
         in a heterogeneous patient population such as ESRD. It is not anticipated that such
         problems will be encountered in our study for several reasons: firstly, this will
         be an inclusive study (rather than having strict inclusion/exclusion criteria); secondly,
         a local pilot study <a name="d80443e549"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>] has demonstrated that 79 patients had TCVCs inserted over a 6-month period and therefore
         might be approached for inclusion in this study.
      </p>
      <p style="line-height:160%">The power calculation for this study is based on a bacteraemia rate of 24% in the
         TCVC arm. This rate is higher than that described in many series, but is derived directly
         from our local pilot study <a name="d80443e555"></a>[<a onclick="LoadInParent('#B19'); return false;" href="#B19">19</a>]. It may be that these higher rates of infection relate to early post-insertion infection
         rates, rather than overall bacteraemia rates for static prevalent TCVCs.
      </p>
   </div>
</section>
<section><a name="sec3"></a><h3>Discussion</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">The purpose of this trial is to investigate the hypothesis that, in patients requiring
         urgent vascular access for haemodialysis, the 6-month culture-proven bacteraemia rate
         is improved by a strategy of ecAVG ± AVF compared to TCVC ± AVF as this has not yet
         been demonstrated in a large randomised controlled trial.
      </p>
      <p style="line-height:160%">Complications of vascular access are a leading cause of morbidity and mortality in
         patients with ESRD. The healthcare costs from a catheter-related bacteraemia range
         from $6,000 to $29,000 <a name="d80443e567"></a>[<a onclick="LoadInParent('#B26'); return false;" href="#B26">26</a>]. If the proposed strategy of ecAVG ± AVF is found to reduce culture-proven bacteraemia
         rates, it could result in significant reduction in healthcare costs and reduced morbidity
         and hospitalisation for patients with ESRD. This could lead to a paradigm shift away
         from TCVC in patients requiring urgent vascular access. Conversely if TCVC ± AVF is
         found to be superior, this finding would support our current strategy of TCVC usage
         in this patient cohort. Therefore, either a positive or negative result will help
         inform future practice regarding the optimal strategy of vascular access in patients
         requiring urgent haemodialysis.
      </p>
   </div>
</section>
<section><a name="sec4"></a><h3>Trial status</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">Recruiting.</p>
      <h4>Finance and indemnity</h4>
      <p style="line-height:160%">A small Investigator Led research grant from W.L. Gore Associates will assist in analysis
         of secondary end-point data. The funders have no role in the study design, data collection
         or analysis, decision to publish or preparation of the manuscript. NHS employed researchers
         will be covered for negligent harm through the NHS CNORIS indemnity scheme.
      </p>
   </div>
</section>
<section><a name="sec5"></a><h3>Abbreviations</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">AVF: arteriovenous fistula</p>
      <p style="line-height:160%">AVG: arteriovenous graft</p>
      <p style="line-height:160%">ecAVG: early cannulation arteriovenous graft</p>
      <p style="line-height:160%">ESRD: end-stage renal disease</p>
      <p style="line-height:160%">SAE: serious adverse event</p>
      <p style="line-height:160%">TCVC: tunnelled central venous catheter</p>
   </div>
</section>
<section><a name="sec6"></a><h3>Competing interests</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">DK has received a small Investigator Led Research Grant from W.L. Gore Associates.
         The remaining authors declare that they have no competing interests.
      </p>
   </div>
</section>
<section><a name="sec7"></a><h3>Authors’ contributions</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">DK conceived the study. EA and DK designed the study. EA wrote the protocol. DK, RK,
         MC, CG, PT and CB reviewed and optimised the protocol. EA is responsible for communicating
         with the Governing Bodies (West of Scotland Research Ethics Committee, NHS Research
         and Development and NHS Finance Departments). EA is the Principle Investigator for
         the study. All authors have read and approved the final version of the manuscript.
      </p>
   </div>
</section>
<section><a name="ack"></a><h3>Acknowledgements</h3>
   <div class="collapsible-content">
      <p style="line-height:160%">We are grateful to David Young, University of Strathclyde, for his statistical advice
         and Kashfa Iqbal, W.L. Gore Associates, for her input regarding health economic analysis.
         A small Investigator Led research grant from W.L. Gore Associates will assist in analysis
         of secondary end-point data. The funders have no role in the study design, data collection
         or analysis, decision to publish or preparation of the manuscript.
      </p>
   </div>
</section>
<section><a name="refs"></a><h3>References</h3>
   <div id="article-references" class="collapsible-content">
      <ol id="references">
         <li id="B1">
            <p><a name="B1"></a>Fluck R, Kumwenda M. Clinical Practice Guidelines Vascular Access for Haemodialysis.
               UK Renal Association 5th Edition, 2011. Published online at: http://www.renal.org/docs/default-source/guidelines-resources/Vascular_Access_for_Haemodialysis_-_FINAL_VERSION_-_05_January_2011.pdf?sfvrsn=0
            </p>
         </li>
         <li id="B2">
            <p><a name="B2"></a> Rayner HC,  Pisoni RL,  Gillespie BW,  Goodkin DA,  Akiba T,  Akizawa T, <em>et al</em>.: <strong> Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis
                  Outcomes and Practice Patterns Study. </strong><p><em>Kidney Int</em> 2003,  <strong>63</strong><strong>:</strong>323-30.  <a target="_blank" href="/pubmed/12472799">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=12472799">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B2" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B2','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B3">
            <p><a name="B3"></a>National Kidney Care Vascular Access Report 2011. http://www.hqip.org.uk/assets/NCAPOP-Library/VAReport2011Interactive03082011-FINAL.pdf.
               Accessed 25 May 2104.
            </p>
         </li>
         <li id="B4">
            <p><a name="B4"></a> Thomson PC,  Stirling CM,  Geddes CC,  Morris ST,  Mactier RA: <strong> Vascular access in haemodialysis patients: a modifiable risk factor for bacteraemia
                  and death. </strong><p><em>QJM</em> 2007,  <strong>100</strong><strong>:</strong>415-22.  <a target="_blank" href="/pubmed/17526532">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17526532">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B4" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B4','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B5">
            <p><a name="B5"></a> Rodriguez JA,  Armadans L,  Ferrer E,  Olmos A,  Codina S,  Bartolome J, <em>et al</em>.: <strong> The function of permanent vascular access. </strong><p><em>Nephrol Dial Transplant</em> 2000,  <strong>15</strong><strong>:</strong>402-8.  <a target="_blank" href="/pubmed/10692528">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=10692528">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B5" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B5','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B6">
            <p><a name="B6"></a> Dember LM,  Beck GJ,  Allon M,  Delmez JA,  Dixon BS,  Greenberg A, <em>et al</em>.: <strong> Effect of clopidogrel on early failure of arteriovenous fistulas for haemodialysis:
                  a randomised controlled trial. </strong><p><em>JAMA</em> 2008,  <strong>299</strong><strong>:</strong>2164-71.  <a target="_blank" href="/pubmed/18477783">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18477783">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B6" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B6','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B7">
            <p><a name="B7"></a>Scottish Renal Registry Report, ISD Scotland. http://www.srr.scot.nhs.uk/Publications/PDF/scottish-renal-registry-report-2013-web.pdf?2.
               Accessed 28 September 2013.
            </p>
         </li>
         <li id="B8">
            <p><a name="B8"></a>Aitken EL, Stevenson KS, Gingell-Littlejohn M, Aitken M, Clancy M, Kingsmore DB. The
               use of tunneled central venous catheters: inevitable or system failure. J Vasc Access.
               2014. doi:10.5301/jva.5000206
            </p>
         </li>
         <li id="B9">
            <p><a name="B9"></a> Ethier J,  Mendelssohn DC,  Elder SJ,  Hasegawa T,  Akizawa T,  Akiba T, <em>et al</em>.: <strong> Vascular access use and outcomes: an international perspective from the dialysis outcomes
                  and practice patterns study. </strong><p><em>Nephrol Dial Transplant</em> 2008,  <strong>23</strong><strong>:</strong>3219-26.  <a target="_blank" href="/pubmed/18511606">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=18511606">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B9" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B9','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B10">
            <p><a name="B10"></a> O’Hare AM,  Bertenthal D,  Walter LC,  Garg AX,  Covinsky K,  Kaufman JS, <em>et al</em>.: <strong> When to refer patients with chronic kidney disease for vascular access surgery: should
                  age be a consideration? </strong><p><em>Kidney Int</em> 2007,  <strong>71</strong><strong>:</strong>555-61.  <a target="_blank" href="/pubmed/17245396">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=17245396">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B10" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B10','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B11">
            <p><a name="B11"></a> Hughes SA,  Mendelssohn JG,  Tobe SW,  McFarlane PA,  Mendelssohn DC: <strong> Factors associated with suboptimal initiation of dialysis despite early nephrologist
                  referral. </strong><p><em>Nephrol Dial Transplant</em> 2013,  <strong>28</strong><strong>:</strong>392-7.  <a target="_blank" href="/pubmed/23222418">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=23222418">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B11" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B11','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B12">
            <p><a name="B12"></a> Bray BD,  Boyd J,  Daly C,  Donaldson K,  Doyle A,  Fox JG, <em>et al</em>.: <strong> Vascular access type and risk of mortality in a national prospective cohort of haemodialysis
                  patients. </strong><p><em>QJM</em> 2012,  <strong>105</strong><strong>:</strong>1097-102.  <a target="_blank" href="/pubmed/22908320">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=22908320">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B12" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B12','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B13">
            <p><a name="B13"></a> Taylor G,  Gravel D,  Johnston L,  Embil J,  Holton D,  Paton S: <strong> Prospective surveillance for primary bloodstream infections occurring in Canadian
                  hemodialysis units. </strong><p><em>Infect Control Hosp Epidemiol</em> 2002,  <strong>23</strong><strong>:</strong>716-20.  <a target="_blank" href="/pubmed/12517012">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=12517012">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B13" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B13','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B14">
            <p><a name="B14"></a> Schild AF: <strong> Maintaining vascular access: the management of haemodialysis arteriovenous grafts. </strong><p><em>J Vasc Access</em> 2010,  <strong>11</strong><strong>:</strong>92-9.  <a target="_blank" href="/pubmed/20155717">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20155717">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B14" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B14','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B15">
            <p><a name="B15"></a> Akoh JA: <strong> Prosthetic arteriovenous grafts for haemodialysis. </strong><p><em>J Vasc Access</em> 2009,  <strong>10</strong><strong>:</strong>137-47.  <a target="_blank" href="/pubmed/19670164">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=19670164">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B15" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B15','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B16">
            <p><a name="B16"></a> Schild AF,  Schuman ES,  Noicely K,  Kaufman J,  Gillaspie E,  Fuller J, <em>et al</em>.: <strong> Early cannulation prosthetic graft (Flixene™) for arteriovenous access. </strong><p><em>J Vasc Access</em> 2011,  <strong>12</strong><strong>:</strong>248-52.  <a target="_blank" href="/pubmed/21319129">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21319129">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B16" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B16','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B17">
            <p><a name="B17"></a> Katzman HE: <strong> A review of prospective trials to evaluate angioaccess graft materials. </strong>In <em>Vascular Access for Haemodialysis VI.W.L</em>.  Edited by Henry ML.  Gore and Associates Inc., Prescott Press, Tyler, TX, USA;  1999:263-72.  <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B17" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B17','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B18">
            <p><a name="B18"></a>Aitken EL, Jackson AJ, Kingsmore DB. Early cannulation prosthetic graft (Acuseal™)
               for arteriovenous access: a useful option to provide a personal vascular access solution.
               J Vasc Access. 2014. doi:10.5301/jva.5000238
            </p>
         </li>
         <li id="B19">
            <p><a name="B19"></a>Aitken EL, Thompson P, Kingsmore DB. Early cannulation arteriovenous grafts (ecAVG)
               for haemodialysis: a viable alternative to tunneled central venous catheters (TCVCs)?
               Clin Nephrol. 2014. in press.
            </p>
         </li>
         <li id="B20">
            <p><a name="B20"></a> Iqbal K,  Aitken E,  Thompson P,  Kingsmore D: <strong> Early cannulation arteriovenous grafts for haemodialysis: a cost-saving alternative
                  to tunneled central venous catheters? An estimated budget impact analysis in a single
                  centre. Poster presentation at 19th ISPOR International Conference, 31 May-4 June
                  2014, Montreal, Canada. </strong><p><em>J Int Soc Socioecon Outcomes Res</em> 2014,  <strong>17</strong>(3)<strong>:</strong>A291.  <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B20" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B20','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B21">
            <p><a name="B21"></a> Sidawy AN,  Gray R,  Besarab A,  Henry M,  Ascher E,  Silva M Jr, <em>et al</em>.: <strong> Recommended standards for reports dealing with arteriovenous access. </strong><p><em>J Vasc Surg</em> 2002,  <strong>35</strong><strong>:</strong>603-10.  <a target="_blank" href="/pubmed/11877717">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=11877717">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B21" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B21','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B22">
            <p><a name="B22"></a> Thomson P,  Stirling C,  Traynor J,  Morris S,  Mactier RA: <strong> A prospective observational study of catheter-related bacteraemia and thrombosis in
                  a haemodialysis cohort: univariate and multivariate analyses of risk association. </strong><p><em>Nephrol Dial Transplant</em> 2010,  <strong>25</strong><strong>:</strong>1596-602.  <a target="_blank" href="/pubmed/20054025">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=20054025">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B22" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B22','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B23">
            <p><a name="B23"></a>Mandolfo S, Acconcia P, Bucci R, Corradi B, Farina M, Rizzo MA, et al. Hemodialysis
               tunneled central venous catheters: five-year outcome analysis. J Vasc Access. 2014.
               doi:10.5301/jva.5000236
            </p>
         </li>
         <li id="B24">
            <p><a name="B24"></a> Harish A,  Allon M: <strong> Arteriovenous graft infection: a comparison of thigh and upper extremity grafts. </strong><p><em>CJASN</em> 2011,  <strong>6</strong><strong>:</strong>1739-43.  <a target="_blank" href="/pubmed/21642365">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21642365">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B24" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B24','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B25">
            <p><a name="B25"></a> Hemmelgarn BR,  Moist LM,  Lok CE,  Tonelli M,  Manns BJ,  Holden RM, <em>et al</em>.: <strong> Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. </strong><p><em>N Engl J Med</em> 2011,  <strong>364</strong><strong>:</strong>303-12.  <a target="_blank" href="/pubmed/21268722">PubMed&nbsp;Abstract</a> | <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&amp;cmd=prlinks&amp;retmode=ref&amp;id=21268722">Publisher&nbsp;Full&nbsp;Text</a> <a href="/sfx_links?ui=s13063-015-0556-x&amp;bibl=B25" onclick="popup('/sfx_links?ui=s13063-015-0556-x&amp;bibl=B25','SFXMenu','460','420'); return false;"><img src="/sfx_links?getImage" alt="OpenURL" align="absmiddle"></a></p>
               <p class="totext"><script type="text/javascript">totext()</script></p>
            </p>
         </li>
         <li id="B26">
            <p><a name="B26"></a>Centre for Disease Control. Cost of catheter related bacteraemia. http://www.cdc.gov/HAI/pdfs/hai/Scott_CostPaper.pdf.
               Accessed 26 May 2014.
            </p>
         </li>
      </ol>
   </div>
</section>
    <br class="clearall">
<div class="article-alert-signup-div">

<a class="close png_bg" id="closeHelpBox" >close</a>	
<div class="article-alert-signup rounded" > 
<span class="blurb left">Sign up to receive new article alerts from <em>Trials</em></span>

	
				<button name="articleAlertPreference.status" type="button" class="w74 right" onClick="window.location='/my/preferences'">Sign up</button>
	
</div>
</div></div>
    </div></div>
</div>


		</div>
</div>

    <hr class="hide" />
	
    

						
   
  
      
  
                  
  
                  
  
            
  
            
            


<div id="footer">

						
			<span class="views"><a id="mobile-view" href="?fmt_view=mobile">Mobile view</a> | <strong>Desktop view</strong></span>
			
	<div class="content">
    <div class="rounded ">
<div class="wrap-inner ">
        	
    <ul class="desktop">
                                                    
				        <li class="noborder"><a href="http://www.biomedcentral.com/about/tandc">Terms and Conditions</a></li>
<li><a href="http://www.biomedcentral.com/about/privacy">Privacy statement</a></li>
<li><a href="http://www.biomedcentral.com/presscenter">Press</a></li>
	<li><a href="http://www.biomedcentral.com/advertisers">Information for advertisers</a></li>
<li><a href="http://www.biomedcentral.com/about/bmcjobs">Jobs at BMC</a></li>
<li><a href="/support">Support</a></li>
<li><a href="/about/contact">Contact us</a></li>


    
    	    </ul>
    <p id="copyright">&copy; 2015 
	BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business&nbsp;Media.</p>
        </div>
</div>

	</div>

</div>
<div class="springer">
    <a href="http://www.springer.com/" target="blank"><img style="float:right; margin:0;" src="
    //www.biomedcentral.com/images/Springer_Branding_footer_logo.png" /></a>
</div>


<script>window.bmcIsMobile = "classic";</script>					    

<script>
// getElementsByClassName Polyfill
var getElementsByClassName=function(e,t,n){if(document.getElementsByClassName){getElementsByClassName=function(e,t,n){n=n||document;var r=n.getElementsByClassName(e),i=t?new RegExp("\\b"+t+"\\b","i"):null,s=[],o;for(var u=0,a=r.length;u<a;u+=1){o=r[u];if(!i||i.test(o.nodeName)){s.push(o)}}return s}}else if(document.evaluate){getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i="",s="http://www.w3.org/1999/xhtml",o=document.documentElement.namespaceURI===s?s:null,u=[],a,f;for(var l=0,c=r.length;l<c;l+=1){i+="[contains(concat(' ', @class, ' '), ' "+r[l]+" ')]"}try{a=document.evaluate(".//"+t+i,n,o,0,null)}catch(h){a=document.evaluate(".//"+t+i,n,null,0,null)}while(f=a.iterateNext()){u.push(f)}return u}}else{getElementsByClassName=function(e,t,n){t=t||"*";n=n||document;var r=e.split(" "),i=[],s=t==="*"&&n.all?n.all:n.getElementsByTagName(t),o,u=[],a;for(var f=0,l=r.length;f<l;f+=1){i.push(new RegExp("(^|\\s)"+r[f]+"(\\s|$)"))}for(var c=0,h=s.length;c<h;c+=1){o=s[c];a=false;for(var p=0,d=i.length;p<d;p+=1){a=i[p].test(o.className);if(!a){break}}if(a){u.push(o)}}return u}}return getElementsByClassName(e,t,n)}
</script>

						



<script type="text/javascript">
if (typeof jQuery == 'undefined') { document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.min.js' type='text/javascript'%3E%3C/script%3E")); }


document.documentElement.id = "js";

var site = {
			abbreviation: "",
	        type: "BMC_NICHE",
        portalId: "9001",
                section: "browse",
                page: "fulltext",
    		
									homePortal: "biomedcentral.com",
		
			siteShowAds: "true",
				showAds: "true",
				url: "trialsjournal.com",
			portal: false,
	        adpage_url: "trialsjournal.com/article/10.1186/s13063/015/0556/x",
        id: "10096",
	name: "Trials",
	plugins: {
		scrollable: (getElementsByClassName("scrollable").length > 0),
				flowplayer: ((document.getElementById("flowplayer") != null) || (getElementsByClassName("myPlayer").length > 0) || (document.getElementById("videoarticle") != null) || (getElementsByClassName("flowplayer").length > 0) || (document.getElementById("audio") != null) || (document.getElementById("elifeplayer") != null)),
		lightbox: ((document.getElementById("image-highlight") != null) || (getElementsByClassName("lightbox").length > 0)),
		thickbox: (getElementsByClassName("thickbox").length > 0),
		altmetric: ((document.getElementById("altmetric") != null) || (getElementsByClassName("altmetric").length > 0))
	}
	
};



if(typeof quoteSearchUri == "undefined") { quoteSearchUri=null; }
</script>



        <script type="text/javascript" src="http://www.bmcimg.com/javascript/journals/behaviours-0.js"></script>






		<script>
	if (site.plugins.scrollable == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.scrollable-1.0.1.min.js' %3E%3C/script%3E")); 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.tools.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.flowplayer == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/flowplayer-3.2.6.min.js'%3E%3C/script%3E"));
	}

	if (site.plugins.lightbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/browse_imagehighlight.js'%3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/jquery.colorbox.js' %3E%3C/script%3E"));
	}

	if (site.plugins.thickbox == true) { 
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-compressed.js' %3E%3C/script%3E"));
		document.write(decodeURIComponent("%3Cscript src='/javascript/plugins/thickbox-flashhidden-patch.js' %3E%3C/script%3E"));
	}
	</script>





            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.fancybox-1.3.1.pack-0.js"></script>
            <script type="text/javascript" src="http://www.bmcimg.com/javascript/plugins/jquery.debug-0.js"></script>
                      <script type="text/javascript" src="http://www.bmcimg.com/javascript/email_preferences/email_preferences-0.js"></script>
                <script type="text/javascript" src="http://www.bmcimg.com/javascript/articles/articles-0.js"></script>
		<div id="fb-root"></div>











        <script type="text/javascript" src="/javascript/plugins/jquery.tagcloud.min-0.js"></script>




<!--[if lte IE 6]>
            <script type="text/javascript" src="/javascript/plugins/DD_belatedPNG_0.0.8a-0.js"></script>
    <script type="text/javascript">
        DD_belatedPNG.fix('.png_bg, ul.primary-nav li a, ul.primary-nav li a span, ul.secondary-nav li a, ul.secondary-nav li a span, ul li i, .plus-button, .facebook, .twitter, .fancy-bg, #fancybox-close');
    </script>
	                <link rel="stylesheet" type="text/css" href="http://www.bmcimg.com/css/hacks/ie6-0.css"/>
    <![endif]-->

<!-- Claudia Whitcombe wanted this comment here -->

       <div class="hide">
      <dl class="google-ad" id="x96banner">
        <dt style="display: block;" class="hide">
          <a class="skyscraper-ad" href="http://www.biomedcentral.com/advertisers/digital_advertising">Advertisement</a>
       </dt>
        <dd>
          <!-- OAS AD 'x96' begin -->
          <script type="text/javascript">
            OAS_AD('x96');
          </script>
        </dd>
      </dl>
    </div>  
    
</body>
</html>

